Module 2 - Treatment Options and Recent Advances in IBD
Launch Date:
July 21, 2022
July 21, 2022
Primary Audience:
Healthcare professionals who treat patients with IBD—gastroenterology HCPs, including advanced practice providers; and primary care HCPs, including advanced practice providers.
Relevant Terms:
Inflammatory bowel disease (IBD), Crohn’s disease (CD), Ulcerative Colitis (UC), novel and emerging therapies, collaborative care, small molecule, biologic agents, therapeutic drug monitoring (TDM), treat-to-target, individualized care
This module provides a review of therapeutic options and considerations for treating IBD. New and emerging agents are discussed along with relevant clinical trial data. Patient and healthcare professional perceptions and principles of collaborative care are also discussed.
Bruce E. Sands MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz
Division of Gastroenterology
Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Bruce E. Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York. Dr Sands was awarded his BA and MD from Boston University and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing a GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr Sands is widely recognized for his clinical investigations of new therapeutics for the inflammatory bowel diseases and has published more than 250 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.1.
Identify the treatment options used for IBD
2.
Explore strategies for individualizing therapy in patients with IBD through collaborative care interactions to improve patient satisfaction and disease outcomes
